ACCC says agreement to settle Revlimid patent suit could violate cartel laws
ACCC 2022-03-23 2:53 pm By Cat Fredenburgh | Melbourne
Please login to bookmark Close

The ACCC has refused to authorise a patent settlement and license agreement between Bristol-Myers Squibb unit Celgene and two generic drug makers who sued to invalidate the patents for its blockbuster cancer drug Revlimid, saying it could distort competition between generic drug makers.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au